Progress in therapy development for amyotrophic lateral sclerosis

Area of Science:

• Neuroscience
• Neurodegenerative Diseases
• Pharmacology

Background:

• Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease with complex genetic and environmental causes.
• Motor neuron degeneration in ALS involves detrimental interactions with non-neuronal cells like astrocytes and microglia, leading to neuroinflammation.
• This neuroinflammation results in protein aggregation, compromised cytoskeletal integrity, and motor neuron death.

Purpose of the Study:

• To review experimental therapeutics tested in murine ALS models and human clinical trials.
• To analyze the reasons behind the frequent failure of preclinical ALS therapies to translate into clinical success.
• To explore emerging therapeutic trends, particularly targeting axon guidance signaling pathways.

Main Methods:

• Review of published literature on experimental therapeutics for ALS.
• Emphasis on studies involving murine ALS models and human clinical trials.
• Analysis of factors contributing to translational challenges in ALS drug development.

Main Results:

• Many experimental therapeutics have shown promise in preclinical ALS models but failed in human trials.
• Neuroinflammation and the complex interplay between neuronal and non-neuronal cells are key pathological features.
• Axon guidance signaling pathways are emerging as potential therapeutic targets for preserving neural structure.

Conclusions:

• Current clinical tools cannot substantially slow ALS progression.
• Understanding the complex etiologies of ALS is crucial for developing effective treatments.
• Targeting axon guidance pathways offers a promising future direction for neuroprotective strategies in ALS.